Drug
Remicade (infliximab)
Remicade (infliximab) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_3
1
25%
Ph not_applicable
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
NCT01936181
completed
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
NCT00725296
completed
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
NCT00818272
completednot_applicable
A Clinical Trial of Infliximab for Uveitis
NCT00273390
Clinical Trials (4)
Showing 4 of 4 trials
NCT01936181Phase 3
A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00725296
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
NCT00818272
Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED)
NCT00273390Not Applicable
A Clinical Trial of Infliximab for Uveitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4